Document Detail

An evaluation of serum soluble CD30 levels and serum CD26 (DPPIV) enzyme activity as markers of type 2 and type 1 cytokines in HIV patients receiving highly active antiretroviral therapy.
MedLine Citation:
PMID:  11678906     Owner:  NLM     Status:  MEDLINE    
This study evaluates serum CD26 (dipeptidyl peptidase IV, DPPIV) enzyme activity and serum levels of soluble CD30 as markers of T1 and T2 cytokine environments in HIV patients who achieved immune reconstitution after highly active antiretroviral therapy (HAART). Patients who had experienced inflammatory disease associated with pre-existent opportunistic infections after HAART (immune restoration diseases, IRD) were considered separately. Serum sCD30 levels and CD26 (DPPIV) enzyme activity were compared with IFN-gamma production by PBMC cultured with cytomegalovirus (CMV) antigen in controls and patient groups. High sCD30 levels were associated with low IFN-gamma production after antigenic stimulation in control subjects and, to a lesser extent, in immune reconstituted HIV patients. There was no association between serum CD26 (DPPIV) enzyme activity and IFN-gamma production or sCD30 levels. Serum sCD30 levels and CD26 (DPPIV) enzyme activity were significantly increased in immune reconstituted patients with high HIV viral loads. Patients who had experienced CMV retinitis as an IRD had significantly higher sCD30 levels than all other patient groups. Hence, high sCD30 levels may be a marker of a T2 cytokine environment in HIV patients with immune reconstitution and are associated with higher HIV viral loads and a history of CMV associated IRD.
N M Keane; P Price; S Lee; S F Stone; M A French
Related Documents :
7667006 - Cmv retinitis.
9170416 - Definition and diagnosis of cytomegalovirus colitis in patients infected by human immun...
8985536 - Pneumocystis carinii and cytomegalovirus infections in severely ill, hiv-infected afric...
15018666 - Avidity of antibodies to cytomegalovirus in hiv-seropositive patients with and without ...
18090396 - Survival following hiv infection of a cohort followed up from seroconversion in the uk.
16282936 - Polymerase chain reaction for diagnosis of human immunodeficiency virus infection in in...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical and experimental immunology     Volume:  126     ISSN:  0009-9104     ISO Abbreviation:  Clin. Exp. Immunol.     Publication Date:  2001 Oct 
Date Detail:
Created Date:  2001-10-26     Completed Date:  2001-12-04     Revised Date:  2013-06-09    
Medline Journal Info:
Nlm Unique ID:  0057202     Medline TA:  Clin Exp Immunol     Country:  England    
Other Details:
Languages:  eng     Pagination:  111-6     Citation Subset:  IM    
Department of Clinical Immunology and Biochemical Genetics, Royal Perth Hospital, Perth, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
AIDS-Related Opportunistic Infections / blood*,  complications,  immunology
Antigens, CD30 / blood*
Antigens, Viral / immunology
Antiretroviral Therapy, Highly Active*
Biological Markers / blood
Cells, Cultured
Cohort Studies
Cytomegalovirus / immunology
Cytomegalovirus Retinitis / blood,  complications,  immunology
Dipeptidyl Peptidase 4 / blood*,  metabolism
HIV / genetics,  isolation & purification
HIV Infections / blood*,  complications,  drug therapy,  immunology
Interferon-gamma / biosynthesis*
Middle Aged
RNA, Viral / blood
Th1 Cells / enzymology,  immunology
Th2 Cells / enzymology,  immunology
Viral Load
Reg. No./Substance:
0/Antigens, CD30; 0/Antigens, Viral; 0/Biological Markers; 0/RNA, Viral; 82115-62-6/Interferon-gamma; EC Peptidase 4

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  In vitro cytokine production and growth inhibition of lymphoblastoid cell lines by CD4+ T cells from...
Next Document:  Mucosal T cells regulate Paneth and intermediate cell numbers in the small intestine of T. spiralis-...